FDA approves Biogen Idec's multiple sclerosis drug
August 15, 2014 at 18:36 PM EDT
Aug 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment.